CCNQ

CCNQ (Cyclin M, FAM58A) encodes an activating cyclin that binds and activates the cyclin-dependent kinase CDK10 to form a heterodimeric protein kinase that governs cell signaling and primary cilium homeostasis (PMID:24218572, PMID:27104747). The CDK10/CyclinM complex phosphorylates ETS2 in vitro and drives its proteasomal degradation in cells; loss of CyclinM phenocopies loss of CDK10 by elevating c-Raf and conferring tamoxifen resistance (PMID:24218572). The complex also phosphorylates PKN2 on threonines 121 and 124 within its RhoA-binding domain, and loss of CDK10/CyclinM (or expression of non-phosphorylatable PKN2) destabilizes RhoA and the actin network, thereby promoting primary cilia assembly and elongation; ectopic RhoA reverses the ciliogenesis induced by complex knockdown (PMID:27104747). STAR/Al Kaissi syndrome-associated CyclinM variants disrupt this complex: classical mutants fail to interact with CDK10, while truncated variants retain heterodimer formation but yield loss of complex kinase activity through proteasomal degradation (PMID:24218572, PMID:34369103). The kinase is biochemically tractable and is potently inhibited in vitro by several known CDK inhibitors (PMID:32175313).

1. 2013 High

   Established that CCNQ functions as the activating cyclin partner of CDK10 and that the resulting kinase controls ETS2 stability and MAPK signaling, answering what molecular activity CCNQ confers and how its disease mutations act.

   Evidence Co-immunoprecipitation, in vitro kinase assay on ETS2, siRNA knockdown, proteasome inhibition, and patient-derived cells

   PMID:24218572

   Open questions at the time

   • Did not address cytoskeletal or ciliary roles
   • ETS2 phosphosites and the in vivo signaling consequences in development not mapped
2. 2016 High

   Identified PKN2 as a CDK10/CyclinM substrate and defined the RhoA-actin axis through which the complex suppresses ciliogenesis, connecting the kinase to a cytoskeletal and ciliary phenotype relevant to STAR syndrome.

   Evidence Unbiased phospho-substrate screen, in vitro kinase assay with site-directed phospho-mapping (Thr121/124), siRNA knockdown, RhoA overexpression rescue, cilia immunofluorescence, and STAR patient kidney sections

   PMID:27104747

   Open questions at the time

   • Mechanism by which PKN2 phosphorylation stabilizes RhoA not resolved at molecular level
   • Tissue-specific contribution of cilia defect to STAR phenotype not established
3. 2017 Medium

   Confirmed independently that loss of CDK10 kinase function impairs ciliogenesis in patient cells, corroborating the CCNQ/CDK10 complex's role in cilium formation.

   Evidence Exome sequencing and cilia immunofluorescence (acetylated-tubulin, γ-tubulin, Arl13b) in patient-derived cells

   PMID:29130579

   Open questions at the time

   • Addresses CDK10 rather than CCNQ directly
   • Cytoskeletal phenotype described only qualitatively
4. 2020 Medium

   Provided a tractable biochemical assay and demonstrated pharmacological inhibitability of the CDK10/CyclinM kinase, enabling future inhibitor and substrate studies.

   Evidence Optimized peptide substrate, miniaturized in vitro kinase assay, and profiling of known CDK inhibitors

   PMID:32175313

   Open questions at the time

   • Inhibitors are not selective for CDK10/CyclinM
   • No cellular validation of inhibition
5. 2021 Medium

   Resolved how STAR/Al Kaissi truncating variants impair the complex, showing heterodimer formation is retained but kinase activity is lost via proteasomal degradation of the subunits.

   Evidence Structural modeling, baculovirus expression with in vitro kinase assay, yeast two-hybrid, and proteasome inhibition in human cells

   PMID:34369103

   Open questions at the time

   • Degradation pathway / E3 ligase not identified
   • In vivo developmental consequence not modeled
6. 2022 Low

   Reported an atypical CCNQ tail-extension variant that reduces cyclin M expression yet increases CDK10-cyclin M binding affinity, indicating disease alleles can act through mechanisms distinct from simple loss of interaction.

   Evidence Whole-exome and Sanger sequencing, mutant construct transfection in cultured cells, and zebrafish embryo transfection

   PMID:36284407

   Open questions at the time

   • Binding-affinity claim not methodologically elaborated
   • Functional consequence on kinase activity and ciliogenesis not directly measured
   • Single lab, not independently confirmed

• How CDK10/CyclinM substrate phosphorylation is integrated to control development across tissues, and whether ETS2 and PKN2 axes act independently or convergently in STAR syndrome pathogenesis, remains unresolved.
• No in vivo model linking specific substrate phosphorylation to organ malformation
• Full substrate repertoire of the kinase unknown